Literature DB >> 16182586

Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex.

Marcelo Lancellotti1, Annie Guiyoule, Corinne Ruckly, Eva Hong, Jean-Michel Alonso, Muhamed-Kheir Taha.   

Abstract

Capsule switching in Neisseria meningitidis is thought to occur by horizontal DNA exchange between meningococcal strains. Antigenic variants may be generated by allelic replacement of the siaD gene; the variants may then be selected by specific immunity against the capsular antigen. There were several vaccination campaigns against serogroup C in France in 2002, following an increase in the prevalence of invasive isolates of serogroup C of the phenotype C:2a:P1.5 and C:2a:P1.5,2 belonging to the ET-37/ST-11 clonal complex. We evaluated the emergence of capsule variants by the detection of B:2a:P1.5 and B:2a:P1.5,2 meningococcal isolates of the ET-37/ST-11 clonal complex. These isolates were significantly more frequent after the year 2002. Pulsed field gel electrophoresis profiles of the serogroup B (ET-37/ST-11) isolates differed from that of serogroup C (ET-37/ST-11) isolates by the bands that harbor the siaD genes responsible for the serogroup specificity. However, serogroup B and C, ET37/ST-11 isolates both express similar virulence as assessed from colonization and invasiveness in a mouse model. Our results indicate that capsule switching events within the same clonal complex can arise frequently with no alteration in virulence. This justifies an enhanced system of surveillance by molecular typing of such isolates, particularly after serogroup-specific vaccination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16182586     DOI: 10.1016/j.micinf.2005.06.012

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  16 in total

Review 1.  Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.

Authors:  Rodolfo Villena; Marco Aurelio P Safadi; María Teresa Valenzuela; Juan P Torres; Adam Finn; Miguel O'Ryan
Journal:  Hum Vaccin Immunother       Date:  2018-04-30       Impact factor: 3.452

2.  Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci.

Authors:  M J Callaghan; S Lewis; M Sadarangani; S E S Bailey; H Chan; D J P Ferguson; J P Derrick; I Feavers; M C Maiden; A J Pollard
Journal:  Infect Immun       Date:  2011-04-04       Impact factor: 3.441

3.  Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba.

Authors:  Yanet Climent; Daniel Yero; Isabel Martinez; Alejandro Martín; Keith A Jolley; Franklin Sotolongo; Martin C J Maiden; Rachel Urwin; Rolando Pajón
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

4.  Recombining population structure of Plesiomonas shigelloides (Enterobacteriaceae) revealed by multilocus sequence typing.

Authors:  Anna Salerno; Alexis Delétoile; Martine Lefevre; Ivan Ciznar; Karel Krovacek; Patrick Grimont; Sylvain Brisse
Journal:  J Bacteriol       Date:  2007-08-10       Impact factor: 3.490

5.  Effect of mesoporous silica under Neisseria meningitidis transformation process: environmental effects under meningococci transformation.

Authors:  Luciana M Hollanda; Gisele Cg Cury; Rafaella Fc Pereira; Gracielle A Ferreira; Andreza Sousa; Edesia Mb Sousa; Marcelo Lancellotti
Journal:  J Nanobiotechnology       Date:  2011-07-25       Impact factor: 10.435

6.  Effects of multi-walled carbon nanotubes (MWCNT) under Neisseria meningitidis transformation process.

Authors:  Ives B Mattos; Danilo A Alves; Luciana M Hollanda; Helder J Ceragiogli; Vitor Baranauskas; Marcelo Lancellotti
Journal:  J Nanobiotechnology       Date:  2011-11-16       Impact factor: 10.435

7.  Rifampin-resistant Neisseria meningitidis.

Authors:  Muhamed-Kheir Taha; Maria Leticia Zarantonelli; Corinne Ruckly; Dario Giorgini; Jean-Michel Alonso
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

8.  Meningococcal disease serogroup C.

Authors:  Félix O Dickinson; Antonio E Pérez; Iván E Cuevas
Journal:  Risk Manag Healthc Policy       Date:  2012-03-08

9.  Sequence Type 4821 Clonal Complex Serogroup B Neisseria meningitidis in China, 1978-2013.

Authors:  Bingqing Zhu; Zheng Xu; Pengcheng Du; Li Xu; Xiaofang Sun; Yuan Gao; Zhujun Shao
Journal:  Emerg Infect Dis       Date:  2015-06       Impact factor: 6.883

10.  Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine.

Authors:  Paul A Kristiansen; Absatou Ky Ba; Idrissa Sanou; Abdoul-Salam Ouédraogo; Rasmata Ouédraogo; Lassana Sangaré; Fabien Diomandé; Denis Kandolo; Jennifer Dolan Thomas; Thomas A Clark; Marc Laforce; Dominique A Caugant
Journal:  BMC Infect Dis       Date:  2013-08-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.